Koninklijke Philips N.V. (PHG)
After hours:
| Previous close | 18.89 |
| Open | 18.92 |
| Bid | 18.55 x 1800 |
| Ask | 18.71 x 1000 |
| Day's range | 18.58 - 18.97 |
| 52-week range | 18.58 - 48.72 |
| Volume | |
| Avg. volume | 1,859,133 |
| Market cap | 17.212B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | 41.44 |
| EPS (TTM) | 0.45 |
| Earnings date | N/A |
| Forward dividend & yield | 0.91 (4.43%) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 42.40 |
- Globe Newswire
Philips to convene Extraordinary General Meeting of Shareholders to appoint Roy Jakobs as new President and Chief Executive Officer
Frans van Houten Roy Jakobs August 18, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today convenes an Extraordinary General Meeting of Shareholders (EGM) and publishes the agenda with explanatory note. The sole purpose of the EGM is to appoint Roy Jakobs as the company’s President and Chief Executive Officer, effective October 15, 2022, as successor to Frans van Houten. The EGM will be held at the Hotel Okura Amsterdam (Ferdinand Bolstraat 333, Amsterdam) on Friday, Sep
- Reuters
FDA says faulty Philips device reports accelerating as CEO departs
The U.S. Food and Drug Administration (FDA) said reports of faulty Philips ventilators and sleep apnea machines had risen in the past quarter, underlining problems facing the Dutch company, which has just announced plans to replace its CEO. Philips says it is approximately halfway through a recall of 5.5 million such devices in the United States due to the threat posed by a foam part they contain -- a problem that has alarmed customers, damaged the company's reputation and helped wipe $30 billion off its market capitalisation. The FDA said on Tuesday it had received 48,000 reports associated with breakdown or suspected breakdown in the foam used in Philips respirators over the three months ending July 31, 2022, more than twice the number of such reports it received between April 2021 and April 2022.
